Keverprazan, a novel potassium-competitive acid blocker: Single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects

(2023) Sufeng Zhou et al.   CTS-Clinical and Translational Science

Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole

(2022) Eunsol Yang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The efficacy and safety of keverprazan, a novel potassium‐competitive acid blocker, in treating erosive oesophagitis: a phase III , randomised, double‐blind multicentre study

(2022) Songfeng Chen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

PHARMACODYNAMICS AND PHARMACOKINETICS OF THE POTASSIUM-COMPETITIVE ACID BLOCKER VONOPRAZAN AND THE PROTON PUMP INHIBITOR LANSOPRAZOLE IN U.S. SUBJECTS

(2022) Loren Laine et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Vonoprazan vs Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial

(2022) Loren Laine et al.   GASTROENTEROLOGY

Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double‐blind, parallel‐controlled trial

(2022) Nian‐di Tan et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers

(2021) Deok Y. Yoon et al.   CTS-Clinical and Translational Science

Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial

(2021) Daisuke Kawai et al.   BMC GASTROENTEROLOGY

Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of Tegoprazan

(2021) Sungpil Han et al.   CLINICAL THERAPEUTICS

The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan

(2021) Darcy J. Mulford et al.   Clinical Pharmacology in Drug Development

Randomized clinical trial: 7‐day vonoprazan‐based versus 14‐day omeprazole‐based triple therapy for Helicobacter pylori

(2021) Chalermrat Bunchorntavakul et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study)

(2020) Toshihisa Takeuchi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Potential proton pump inhibitor–related adverse effects

(2020) Issac E. Perry et al.   ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

Pharmacologic treatment of GERD: Where we are now, and where are we going?

(2020) Carmelo Scarpignato et al.   ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects

(2020) Jinjie He et al.   CLINICAL DRUG INVESTIGATION

Diagnosis and Treatment of Peptic Ulcer Disease

(2019) Robert T. Kavitt et al.   AMERICAN JOURNAL OF MEDICINE

Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects

(2019) Sungpil Han et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Peptic ulcer disease

(2019) Emma Sverdén et al.   BMJ-British Medical Journal

Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects

(2018) J. Sunwoo et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Presentation and Epidemiology of Gastroesophageal Reflux Disease

(2018) Joel E. Richter et al.   GASTROENTEROLOGY

Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use

(2018) Yoshikazu Kinoshita et al.   Journal of Neurogastroenterology and Motility

Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases

(2018) Tadayuki Oshima et al.   Journal of Neurogastroenterology and Motility

KFP-H008 blocks gastric acid secretion through inhibiting H + -K + -ATPase

(2017) Cheng-yuan Li et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Peptic ulcer disease

(2017) Angel Lanas et al.   LANCET

Gastroesophageal Reflux Disease

(2017) Rick Kellerman et al.   PRIMARY CARE

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study

(2015) Y. Sakurai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Gastroesophageal Reflux Disease

(2015) Ian G. Harnik   ANNALS OF INTERNAL MEDICINE

The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations

(2015) Hirotoshi Echizen   CLINICAL PHARMACOKINETICS

Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease

(2013) Philip O Katz et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Ghrelin and gastric acid secretion

(2008) Koji Yakabi et al.   WORLD JOURNAL OF GASTROENTEROLOGY